Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.

Competing Interests: Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University (2022-316). Patient data were collected after informed consent was obtained in accordance with the Declaration of Helsinki.